Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Atea Pharmaceuticals, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 108
- +4 vs. Q2 2024
- Shares held
- 57.9M
- +10.3M (+21.7%) vs. Q2 2024
- Total value
- $194.0M
- +$36.5M (+23.2%) vs. Q2 2024
- New holders
- 15
- 40 more added
- Sold out
- 11
- 29 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AVIR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 124 | $276.4M |
| Q1 2026 | 127 | $322.8M |
| Q4 2025 | 111 | $203.5M |
| Q3 2025 | 115 | $154.2M |
| Q2 2025 | 107 | $189.7M |
| Q1 2025 | 104 | $158.3M |
| Q4 2024 | 107 | $188.7M |
| Q3 2024 | 108 | $194.0M |
| Q2 2024 | 105 | $187.7M |
| Q1 2024 | 113 | $219.6M |
| Q4 2023 | 108 | $168.3M |
| Q3 2023 | 119 | $170.6M |
| Q2 2023 | 133 | $213.3M |
| Q1 2023 | 131 | $190.2M |
| Q4 2022 | 131 | $278.1M |
| Q3 2022 | 126 | $326.8M |
| Q2 2022 | 128 | $408.7M |
| Q1 2022 | 127 | $396.6M |
| Q4 2021 | 143 | $479.2M |
| Q3 2021 | 142 | $1.99B |
| Q2 2021 | 104 | $1.27B |
| Q1 2021 | 82 | $3.20B |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Atea Pharmaceuticals, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 1,924,773 | $6.45M | 0.00% | −85,030−4.2% | Reduced |
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $8.33M | 0.87% | 00.0% | Unchanged |
| Tang Capital Management LLC | 4,607,060 | $15.4M | 1.10% | +130,319+2.9% | Added |
| Vanguard Group Inc | 4,851,218 | $16.3M | 0.00% | +126,813+2.7% | Added |
| EcoR1 Capital, LLC | 5,441,896 | $18.2M | 0.62% | 00.0% | Unchanged |
| FMR LLC | 6,618,297 | $22.2M | 0.00% | +182,174+2.8% | Added |
| BML Capital Management, LLC | 6,650,000 | $22.3M | 13.11% | +274,379+4.3% | Added |
| BlackRock, Inc. | 8,990,734 | $30.1M | 0.00% | +8,990,734 | New |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −182,326−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −34,045−100.0% | Sold out |
| Toroso Investments, LLC | 0 | $0 | 0.00% | −18,419−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −11,425−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −8,235−100.0% | Sold out |
| Redwood Wealth Management Group, LLC | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Rothschild Investment LLC | 0 | $0 | 0.00% | −3,150−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −3,028−100.0% | Sold out |
| Frazier Financial Advisors, LLC | 0 | $0 | 0.00% | −120−100.0% | Sold out |
| Smartleaf Asset Management LLC | 0 | $0 | 0.00% | −46−100.0% | Sold out |
| Colonial Trust Advisors | 0 | $0 | 0.00% | −46−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |